Glaxo Flovent Diskus
Fluticasone inhalational powder for Diskus delivery device will not be marketed until 2001, the company said following Sept. 29 approval of the product for maintenance of treatment of asthma as prophylactic therapy for patients four and above. The product is also indicated for patients requiring oral corticosteroid therapy for asthma. Fluticasone is currently marketed in a metered dose inhaler and in a Rotadisk dry powder inhaler. The Flovent Diskus NDA was submitted in March 1998 and has been "approvable" since March 31, 1999 (1"The Pink Sheet" Dec. 6, 1999, p. 8)
You may also be interested in...
Glaxo Wellcome's Flovent Diskus would be a useful option for titration in conjunction with the Advair Diskus, FDA's Pulmonary-Allergy Drugs Advisory Committee suggested at its Nov. 23 meeting.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials